GLUEMonte Rosa Therapeutics Inc. Common Stock

14.30USD-9.32%Mkt Cap: 1.22B $P/E:

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutical…

Key Statistics

Company
Market Cap1.22B $
Enterprise Value677.82M $
Revenue (TTM)28.73M $
Gross Profit-133.63M $
Net Income (TTM)-38.63M $
Revenue/Share0.3110 USD
Last Price14.30 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees173
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN
Valuation
P/E (Trailing)
P/E (Forward)-7.88
PEG
EV/EBITDA-3.90
EV/Revenue23.60
P/S43.89
P/B2.59
EPS (TTM)-1.64
EPS (Forward)-1.88
52W Range
4.30047% of range25.77
52W High25.77 USD
52W Low4.300 USD
Profitability
Gross Margin0.00%
Oper. Margin-547.84%
EBITDA Margin0.00%
Profit Margin-31.23%
ROE-16.57%
ROA-8.61%
Growth
Revenue Growth-61.30%
Earnings Growth
Cash Flow & Leverage
Operating CF-22.80M $
CapEx (TTM)4.70M $
FCF Margin-259.16%
FCF Yield-6.10%
Net Debt-583.12M $
Net Debt/EBITDA3.36
Balance Sheet
Debt/Equity0.17
Current Ratio10.58
Quick Ratio10.49
Book Value/Sh5.717 USD
Cash/Share7.280 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)28.50 USD
Upside (mean)+99.3%
Target Range25.00 USD37.00 USD
$25.00+99.3% to mean$37.00
# Analysts6
Ownership
Shares Out.85.31M
Float54.48M
Insiders0.56%
Institutions115.73%
Short Interest
Short Ratio10.9d
Short % Float19.59%
Short % Out.19.29%
Shares Short16.46M
Short (prev mo.)18.63M
Technical
SMA 5020.03 (-28.6%)
SMA 20018.48 (-22.6%)
Beta1.53
S&P 52W Chg18.16%
Avg Vol (30d)1.35M
Avg Vol (10d)858.24K
Technical Indicators
RSI (14)28.3
MACD-1.7089
MACD Signal-1.5255
MACD Hist.-0.1834
BB Upper24.14 USD
BB Middle17.71 USD
BB Lower11.27 USD
BB Width72.69%
ATR (14)1.238 USD
Vol Ratio (20d)0.64x